FINAL REPORT

| Bill No. | F | APHHC240000543 | Bill Date | I | 22-03-2024 11:26 | | | |
|-----------------|---|---------------------|-----------------------|---|------------------|--|--|--|
| Patient Name | F | MR. BHOLA PRASAD | UHID | | APH000021770 | | | |
| Age / Gender | F | 37 Yrs 1 Mth / MALE | Patient Type | | OPD If PHC : | | | |
| Ref. Consultant | 1 | MEDIWHEEL | Ward / Bed | | 1 | | | |
| Sample ID | 1 | APH24010835 | Current Ward / Bed | | 1 | | | |
| | 1 | | Receiving Date & Time | | 22-03-2024 15:58 | | | |
| | Γ | | Reporting Date & Time | : | 22-03-2024 17:22 | | | |

BIOCHEMISTRY REPORTING

| Test (Methodology) | Flag | Result | UOM | Biological Reference | |
|--|------|--------|-----|----------------------|--|
| | | | | Interval | |
| Sample Type: FDTA Whole Blood, Plasma, Serum | | • | - | | |

Sample Type: EDTA Whole Blood, Plasma, Serum

MEDIWHEEL FULL BODY HEALTH CHECKUP_MALE(BELOW-40)@2400

| BLOOD UREA Urease-GLDH,Kinetic | | 15 | mg/dL | 15 - 45 |
|---|---|-------|-------|-----------|
| BUN (CALCULATED) | | 7.0 | mg/dL | 7 - 21 |
| CREATININE-SERUM (Modified Jaffe's Kinetic) | L | 0.5 | mg/dL | 0.9 - 1.3 |
| GLUCOSE-PLASMA (FASTING) (UV Hexokinase) | Н | 110.0 | mg/dL | 70 - 100 |

Note: A diagnosis of diabetes mellitus is made if fasting blood glucose exceeds 126 mg/dL. (As per American Diabetes Association recommendation)

| | | | |
|--|-------|-------|----------|
| GLUCOSE-PLASMA (POST PRANDIAL) (UV Hexokinase) | 111.0 | mg/dL | 70 - 140 |

Note: A diagnosis of diabetes mellitus is made if 2 hour post load glucose exceeds 200 mg/dL. (As per American Diabetes Association recommendation)

LIPID PROFILE

| CHOLESTROL-TOTAL (CHO-POD) | Н | 232 | mg/dL | 0 - 160 |
|--|---|-------|-------|---|
| HDL CHOLESTROL Enzymatic Immunoinhibition | | 41 | mg/dL | >40 |
| CHOLESTROL-LDL DIRECT Enzymatic Selective Protection | Н | 165 | mg/dL | 0 - 100 |
| S.TRIGLYCERIDES (GPO - POD) | Н | 210 | mg/dL | 0 - 160 |
| NON-HDL CHOLESTROL | Н | 191.0 | mg/dL | 0 - 125 |
| TOTAL CHOLESTROL / HDL CHOLESTROL | | 5.7 | | 1/2Average Risk <3.3 Average Risk 3.3-4.4 2 Times Average Risk 4.5-7.1 3 Times Average Risk 7.2-11.0 |
| LDL CHOLESTROL / HDL CHOLESTROL | | 4.0 | | 1/2Average Risk < 1.0 Average Risk 1.0-3.6 2 Times Average Risk 3.7-6.3 3 Times Average Risk 6.4-8.0 |
| CHOLESTROL-VLDL | Н | 42 | mg/dL | 10 - 35 |

Comments:

- Disorders of Lipid metabolism play a major role in atherosclerosis and coronary heart disease.
- There is an established relationship between increased total cholesterol & LDL cholesterol and myocardial infarction.
- HDL cholesterol level is inversely related to the incidence of coronary artery disease.
- Major risk factors which adversely affect the lipid levels are:
 - 1. Cigarette smoking.
 - 2. Hypertension.
 - 3. Family history of premature coronary heart disease.
 - 4. Pre-existing coronary heart disease.

LIVER FUNCTION TESTS (LFT)

| BILIRUBIN-TOTAL (DPD) | 0.93 | mg/dL | 0.2 - 1.0 |
|--------------------------|------|-------|-----------|
| BILIRUBIN-DIRECT (DPD) | 0.13 | mg/dL | 0 - 0.2 |
| BILIRUBIN-INDIRECT | 0.80 | mg/dL | 0.2 - 0.8 |
| S.PROTEIN-TOTAL (Biuret) | 6.6 | g/dL | 6 - 8.1 |

FINAL REPORT

| ill No. | | APHHC240000543 | Bill Date | | | : | : 22-03-2024 11:26 | | | | |
|------------------------------------|-----|---------------------------------|-----------------------|---------------------|--------------------|--------|--------------------|------------------|-----------|--|--|
| atient Name : MR. BHOLA PRASAD | | | | UHID | | : | APH000021770 | 21770 | | | |
| Age / Gender : 37 Yrs 1 Mth / MALE | | 37 Yrs 1 Mth / MALE | | | Patient Type | : | : | OPD If P | If PHC : | | |
| ef. Consultant | | MEDIWHEEL | | | Ward / Bed | : | : | 1 | | | |
| ample ID | | APH24010835 | | | Current Ward / Bed | : | : | 1 | | | |
| | | | | Receiving Date & Ti | | Time : | | 22-03-2024 15:58 | | | |
| | П | | Reporting Date & Time | | | ne : | : | 22-03-2024 17:22 | | | |
| ALBUMIN-SERU | JM | (Dye Binding-Bromocresol Green) | | 4.1 | ĺ | g/dL | | | | | |
| S.GLOBULIN | | | L | 2. | 5 | g/dL | | 2.8-3.8 | | | |
| A/G RATIO | | | | 1.6 | .64 | | | 1.5 - 2.5 | 1.5 - 2.5 | | |
| ALKALINE PHO | SP | HATASE IFCC AMP BUFFER | | 74 | .2 | IU/L | | 53 - 128 | | | |
| ASPARTATE AN | 1I1 | NO TRANSFERASE (SGOT) (IFCC) | | 29 | .9 | IU/L | | 10 - 42 | | | |
| ALANINE AMIN | 0 | TRANSFERASE(SGPT) (IFCC) | Н | 41 | .2 IU/L | | | 10 - 40 | 10 - 40 | | |
| GAMMA-GLUTA | M | YLTRANSPEPTIDASE (IFCC) | | 30 | .0 | IU/L | | 11 - 50 | 11 - 50 | | |
| LACTATE DEHY | /DI | ROGENASE (IFCC; L-P) | Н | 26 | 61.7 | IU/L | | 0 - 248 | | | |
| S.PROTEIN-TO | TΑ | L (Biuret) | | 6.6 | 5 | g/dL | | 6 - 8.1 | | | |
| URIC ACID Uricas | | Trinder | | 4.4 | 1 | mg/dL | | 2.6 - 7.2 | | | |

** End of Report **

IMPORTANT INSTRUCTIONS
CL - Critical Low, CH - Critical High, H - High, L - Low

DR. ASHISH RANJAN SINGH

MBBS,MD CONSULTANT

FINAL REPORT

| Bill No. | : | APHHC240000543 | Bill Date | : | 22-03-2024 11:26 | | | |
|-----------------|---|---------------------|-----------------------|---|------------------|--------|---|--|
| Patient Name | : | MR. BHOLA PRASAD | UHID | | APH000021770 | | | |
| Age / Gender | : | 37 Yrs 1 Mth / MALE | Patient Type | | OPD | If PHC | : | |
| Ref. Consultant | : | MEDIWHEEL | Ward / Bed | | 1 | | | |
| Sample ID | : | APH24010835 | Current Ward / Bed | : | 1 | | | |
| | : | | Receiving Date & Time | : | 22-03-2024 15:58 | | | |
| | | | Reporting Date & Time | : | 22-03-2024 17:22 | | | |

Sample Type: EDTA Whole Blood, Plasma, Serum

MEDIWHEEL FULL BODY HEALTH CHECKUP_MALE(BELOW-40)@2400

| HBA1C (Turbidimetric Immuno-inhibition) | 6.2 | % | 4.0 - 6.2 |
|---|-----|---|-----------|

INTERPRETATION:

| HbA1c % | Degree of Glucose Control |
|-----------|---|
| >8% | Action suggested due to high risk of developing long term complications like Retinopathy, Nephropathy, Cardiopathy and Neuropathy |
| 7.1 - 8.0 | Fair Control |
| <7.0 | Good Control |

Note:

- 1.A three monthly monitoring is recommended in diabetics.
- 2. Since HbA1c concentration represents the integrated values for blood glucose over the preceding 6 10 weeks and is not affected by daily glucose fluctuation, exercise and recent food intake, it is a more useful tool for monitoring diabetics.

** End of Report **

IMPORTANT INSTRUCTIONS
CL - Critical Low, CH - Critical High, H - High, L - Low

DR. ASHISH RANJAN SINGH

MBBS,MD CONSULTANT